Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

Merat Karbasian-Esfahani, Peter H. Wiernik, Yelena Novik, Elisabeth M. Paietta, Janice P. Dutcher

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND. Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. METHODS. The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily × 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated. RESULTS. Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyorype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis. CONCLUSIONS. The regimen of idarubicin and ara-C achieved a 55% overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however.

Original languageEnglish (US)
Pages (from-to)1414-1419
Number of pages6
JournalCancer
Volume101
Issue number6
DOIs
StatePublished - Sep 15 2004
Externally publishedYes

Fingerprint

Idarubicin
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Resistance
Mucositis
Survival
Drug Combinations
Leukocyte Count
Intravenous Injections
Recurrence
Drug Therapy

Keywords

  • Acute lymphocytic leukemia
  • Cytosine arabinoside
  • Idarubicin
  • Recurrent and refractory acute lymphocytic leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. / Karbasian-Esfahani, Merat; Wiernik, Peter H.; Novik, Yelena; Paietta, Elisabeth M.; Dutcher, Janice P.

In: Cancer, Vol. 101, No. 6, 15.09.2004, p. 1414-1419.

Research output: Contribution to journalArticle

Karbasian-Esfahani, Merat ; Wiernik, Peter H. ; Novik, Yelena ; Paietta, Elisabeth M. ; Dutcher, Janice P. / Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. In: Cancer. 2004 ; Vol. 101, No. 6. pp. 1414-1419.
@article{eec807e2dbe648b2bca45862a2edee7b,
title = "Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia",
abstract = "BACKGROUND. Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. METHODS. The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily × 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated. RESULTS. Six patients (30{\%}) achieved complete remission (CR), 5 (25{\%}) had a partial response (PR), and 9 (45{\%}) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyorype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis. CONCLUSIONS. The regimen of idarubicin and ara-C achieved a 55{\%} overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however.",
keywords = "Acute lymphocytic leukemia, Cytosine arabinoside, Idarubicin, Recurrent and refractory acute lymphocytic leukemia",
author = "Merat Karbasian-Esfahani and Wiernik, {Peter H.} and Yelena Novik and Paietta, {Elisabeth M.} and Dutcher, {Janice P.}",
year = "2004",
month = "9",
day = "15",
doi = "10.1002/cncr.20494",
language = "English (US)",
volume = "101",
pages = "1414--1419",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

AU - Karbasian-Esfahani, Merat

AU - Wiernik, Peter H.

AU - Novik, Yelena

AU - Paietta, Elisabeth M.

AU - Dutcher, Janice P.

PY - 2004/9/15

Y1 - 2004/9/15

N2 - BACKGROUND. Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. METHODS. The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily × 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated. RESULTS. Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyorype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis. CONCLUSIONS. The regimen of idarubicin and ara-C achieved a 55% overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however.

AB - BACKGROUND. Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. METHODS. The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily × 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated. RESULTS. Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyorype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis. CONCLUSIONS. The regimen of idarubicin and ara-C achieved a 55% overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however.

KW - Acute lymphocytic leukemia

KW - Cytosine arabinoside

KW - Idarubicin

KW - Recurrent and refractory acute lymphocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=4444346719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444346719&partnerID=8YFLogxK

U2 - 10.1002/cncr.20494

DO - 10.1002/cncr.20494

M3 - Article

C2 - 15368329

AN - SCOPUS:4444346719

VL - 101

SP - 1414

EP - 1419

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -